SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Cannabis >

Cannabics Pharmaceuticals Inc. (CNBX)

Add CNBX Price Alert      Hide Sticky   Hide Intro
Moderator: captainscotty, Quokkie, WallyWest
Search This Board: 
Last Post: 3/27/2017 8:39:36 PM - Followers: 133 - Board type: Free - Posts Today: 0




Cannabics Pharmaceuticals is dedicated to the development of Personalized Anti-Cancer treatments.

Our main focus is the development of novel therapies and biotechnological tools aimed to providing relief from diverse ailments and treat human malignancies. These advanced tools include novel delivery systems, personalized medicine diagnostics and therapies based on Cannabinoid compounds.

Cannabics scientific research is devoted to create tailored therapies for cancer patients, utilizing advanced High-throughput screening (HTS) diagnostics and personalized bioinformatics tools.

The Company’s principal product is Cannabics SR' a long acting oil capsule that provides a safe, effective and reliable administration of cannabis. Composed solely from food grade materials, Cannabics SR' 5-10mg delivers a steady level of beneficial effects for 4–8 hours.

Cannabics Pharmaceuticals Inc. is traded in the US OTC stock exchange, under the trade symbol: CNBX


October 20, 2016 Cannabics Pharmaceuticals Discovers Specific Ratios of THC/CBD Effectuate Reduction in U87MG Glioblastoma Cell Viability

September 28, 2016 How this tiny Middle Eastern nation came to lead the world in medical marijuana research

June 6, 2016, Cannabics Pharmaceuticals has Filed a PCT Application, Covering a Novel Personalized Anti-Cancer Diagnostics System.


"Cannabics SR', is a long acting oil capsule that provides a safe, effective and reliable administration of cannabis."


Cannabics SR' Capsules, Technology Description - Route of administration


There is a growing number of patients, worldwide, who could benefit from the therapeutic properties of cannabinoids. The unmet need of these patients is a safe, standardized and easy to administer cannabinoid-based therapy. Cannabinoid administration is mainly through smoking, vaporizing, sublingual and oral. While clinical studies show contradictory data regarding a correlation between smoking cannabis and respiratory diseases, most physicians agree that smoking medical cannabis, while having its benefits, is not a healthy nor standardized therapy. 

The pharmacokinetics of THC varies as a function of its route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes; psychotropic effects start within seconds to a few minutes, reach a maximum after 15–30 minutes, and taper off within 2–3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30–90 minutes, reach their maximum after 2–3 hours and last for about 4–12 hours, depending on dose and specific effect. Another common route of administration is sublingually. Pure cannabinoids are extracted from the raw plant, dissolved in different oils and administered with a dropper. The beneficial effect of sublingual oil administration is 2-4 hours with a fast onset due to quick absorption through the oral cavity.

The most common oral administration of cannabinoids is through eating edibles, mainly, cookies, chocolate bars and lozenges. Since absorption is attenuated when cannabinoids are ingested orally, Edibles usually contain high dosages of cannabinoids (50-300mg). The high dosage may cause undesirable side effects, mainly, dizziness, anxiety and dissociation. These side effects cause many patients to withdraw from the therapeutic process.  The oral administration route has the longest beneficial effect (4-8 hours) and lacks the undesirable effects of smoking.

Technology currently envisions the licensing of three different formulations: capsules with a 10:1 CBD to THC ratio, a 10:1 THC to CBD ratio and a balanced formulation with 1:1 THC:CBD.

Cannabics Pharmaceuticals Inc. does not manufacture, distribute, dispense or possess any controlled substances, including cannabis or cannabis based preparations.
CNBX Security Details
Share Structure
  Market Value1 $72,404,107 a/o Jan 13, 2017
Authorized Shares 900,000,000 a/o Dec 30, 2016
Outstanding Shares 107,265,344 a/o Dec 30, 2016
-Restricted 90,368,887 a/o Dec 30, 2016
-Unrestricted 16,896,457 a/o Dec 30, 2016
  Held at DTC Not Available
Float 14,295,638 a/o Jun 30, 2016
  Par Value 0.0001

CNBX Security Details
Share Structure
  Market Value1 $37,994,466 a/o Oct 28, 2016
  Authorized Shares 900,000,000 a/o Jul 09, 2015
  Outstanding Shares 107,026,665 a/o Jun 30, 2016
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 18,737,071 a/o Jun 30, 2016
  Par Value 0.0001

Cannabics Pharmaceuticals Inc. is a US based company founded in 2012 by Israeli researchers from the fields of molecular biology and cancer.
The Company's scientific focus is on harnessing the proven therapeutic properties of natural Cannabinoids and to create tailored therapies for cancer patients, utilizing advanced HTS technology and personalized bioinformatics tools.
The Company's R&D is based in Israel, where it is fully licensed by The Ministry of Health and involves both scientific and academic research as well as current ongoing medical clinical studies which are registered with the US NIH.

The Company new clinical study examine the effectiveness of Cannabics SR capsules as treatment to improve cancer related CACS (Cachexia and Anorexia) in advanced cancer Patients. While this study is taking place in Israel, it is fully registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", identifier NCT02359123 and can be found at:

What is A Cannabinoid?

You’ve heard by now that marijuana is a powerful medicinal herb. But, just how powerful is it? The list of medical benefits for these top 10 cannabinoids seems endless.


Cannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome...!

BETHESDA, Maryland, Jan. 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced development of Cannabics 5mg THC Capsule intended for naïve patient who have not tried cannabis in the past.

Dr. Eyal Ballan, Chief scientist of Cannabics Pharmaceuticals stated, "Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on other."

The Cannabics 5mg THC capsule is currently being evaluated by the company in a clinical study as a palliative treatment, which is conducted by the oncology department at the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.

The study is taking place in Israel, it is fully registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", Identifier NCT02359123, and may be found at :

"The majority of our cancer trial patients have no previous experience with Cannabis, hence this recalibration of the THC level may be more amenable. We believe there is a significant potential medical market for our 5mg THC capsule in countries that have now instituted medical cannabis regulations," said Itamar Borochov, CEO of Cannabics Pharmaceuticals Inc.


<img alt="" data-cke-saved-src=""="" rel="nofollow" target="_blank">"; style="height:398px; width:400px">


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CNBX News: Securities Registration Statement (simplified Form) (s-3) 03/21/2017 01:18:21 PM
CNBX News: Amended Annual Report (10-k/a) 03/15/2017 12:52:22 PM
CNBX News: Israeli Innovation is at the Heart of a Growing Cannabis Ecosystem 02/08/2017 08:30:00 AM
CNBX News: Quarterly Report (10-q) 01/17/2017 12:03:56 PM
CNBX News: Report of Proposed Sale of Securities (144) 12/21/2016 02:05:02 PM
#568  Sticky Note Cannabics Pharmaceuticals Announces a New Dosage of 5mg captainscotty 01/15/17 09:13:10 PM
#1443   Not sure where you are getting your DD jim992 03/27/17 08:39:36 PM
#1442   Cnbx still stellar in my book. I see gsobes 03/27/17 07:11:07 PM
#1441   CNBX vs TXTM(MJ pharmaceutical stocks comparisons). legalizeMJ 03/27/17 01:24:07 PM
#1440   Thanks, I am in that as well. jim992 03/26/17 05:07:20 PM
#1439   Nice DD, Check out OWC# - better financial SeeingGreen420 03/26/17 08:49:41 AM
#1438   Reasons Israel Is Relevant To Cannabics (CNBX): jim992 03/26/17 01:45:50 AM
#1437   CNBX in "6 Pot Stocks Set To Surge", jim992 03/26/17 01:11:47 AM
#1436   #CNBX:Loading up for the next run...:-] $2.87 captainscotty 03/25/17 08:32:43 PM
#1435   Feel free to do some DD. CNBX is Midnightmatt 03/24/17 11:48:09 AM
#1434   How relevant is Israel to this stock's value? mariosmack 03/23/17 09:11:10 PM
#1433   I was just looking at CNBX, which is mariosmack 03/22/17 11:27:45 PM
#1432   Mario thinking to get in this time if Wormking777 03/22/17 05:16:07 PM
#1431   2.70 seems a bit dangerous. I think mariosmack 03/22/17 10:37:17 AM
#1430   Well many shares up for sale now.. someone RigorousGains 03/22/17 08:32:19 AM
#1429   Mario missed both but I'm patient . Last Wormking777 03/21/17 12:33:41 PM
#1428   Where is the news on the clinical trials Chicagojosh 03/21/17 11:42:06 AM
#1427   I never ended up buying CNBX. Blown mariosmack 03/21/17 10:40:50 AM
#1426   CNBX gets a positive mention in another article: jim992 03/21/17 02:52:50 AM
#1425   #CNBX: Looks like that bull flag just got captainscotty 03/20/17 06:31:39 PM
#1424   $CNBX 51% of the volume was SOLD SHORT MjPlayz 03/18/17 08:19:56 AM
#1423   Stock will be manipulated to hit between $4 jim992 03/18/17 01:48:26 AM
#1422   What does an amendment have to do with WallyWest 03/17/17 08:10:32 PM
#1421   For an early stage company, of course it's WallyWest 03/17/17 08:06:15 PM
#1420   Lol, standard language for an auditor report? clicktock 03/17/17 05:26:28 PM
#1419   Again, standard risk factors. Read the WallyWest 03/17/17 04:51:49 PM
#1418   That's standard language for an auditor's report. WallyWest 03/17/17 04:50:08 PM
#1417   Thank you clicktock. Was asking beyond what jim992 03/17/17 02:51:46 PM
#1416   As I said, you can read the amended clicktock 03/17/17 02:42:18 PM
#1415   RE: #1413, Can anyone provide substantial support in jim992 03/17/17 02:22:05 PM
#1414   CNBX bullish 2.43 stocktrademan 03/17/17 01:46:41 PM
#1413   From CNBX's Amended Annual Report (10-k/a) clicktock 03/17/17 12:19:53 PM
#1412   Mario yeah I seen yesterday's number. Would like Wormking777 03/17/17 09:13:17 AM
#1409   NEWS COMING! A Hard Look at Cannabics MjPlayz 03/17/17 07:01:42 AM
#1408   Charts looking Great! NEWS IS COMING IN REGARDS MjPlayz 03/17/17 06:56:18 AM
#1407   when you say volume back to 1 million, mariosmack 03/16/17 11:53:15 PM
#1406   yes, i cancelled my bid. I actually mariosmack 03/16/17 11:48:52 PM
#1405   I started buying some today. Should pop gsobes 03/16/17 10:03:27 PM
#1404   stock is trading at $2.30 now. Jrock25 03/16/17 11:46:40 AM
#1403   it's weird to look at a stock like Jrock25 03/16/17 11:45:19 AM
#1402   Like to see it at 2.00 and volume Wormking777 03/16/17 10:29:08 AM
#1401   Study Start Date: mariosmack 03/16/17 10:21:59 AM
#1400   Mario you hear any news on this stock ? Wormking777 03/16/17 10:07:11 AM
#1399   Have it in at 2.00 for now. This Wormking777 03/16/17 09:59:57 AM
#1398   take a look at this stock. What mariosmack 03/16/17 09:38:51 AM
#1397   Tony 3k @ 2.00 I have pending Wormking777 03/16/17 09:38:29 AM
#1396   Biopsies began last Friday (3/10) and the effects jim992 03/16/17 09:00:05 AM
#1395   Even If Trump Challenges The Marijuana Industry, The MjPlayz 03/16/17 07:28:16 AM
#1394   CNBX Commercialization will commence in March 2017, when MjPlayz 03/16/17 07:27:29 AM